Literature DB >> 21276040

Chronic kidney disease growth factors in renal fibrosis.

Peter Boor1, Jürgen Floege.   

Abstract

1. The common pathological alteration in virtually every progressive chronic kidney disease (CKD) is renal fibrosis. 2. This review focuses on some growth factors, which are particularly well-established in contributing to fibrosis, such as the profibrotic, transforming growth factor-β, and connective tissue growth factor (CTGF), as well as the antifibrotic, bone morphogenic protein 7. The role of other growth factors is only starting to emerge (e.g. platelet-derived growth factor), and the role of yet others remains unclear (e.g. vascular endothelial growth factor). 3. Whether circulating or excreted, growth factors might serve as biomarkers of renal fibrosis and CKD remains largely unanswered. 4. Animal studies suggest that manipulation of growth factors might be an effective treatment option for patients with renal fibrosis and CKD. So far, only inhibition of CTGF is being tested in patients with diabetic nephropathy.
© 2011 The Authors. Clinical and Experimental Pharmacology and Physiology © 2011 Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21276040     DOI: 10.1111/j.1440-1681.2011.05487.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  36 in total

Review 1.  Cellular and molecular mechanisms of renal fibrosis.

Authors:  Youhua Liu
Journal:  Nat Rev Nephrol       Date:  2011-10-18       Impact factor: 28.314

2.  Macrophage Migration Inhibitory Factor Limits Renal Inflammation and Fibrosis by Counteracting Tubular Cell Cycle Arrest.

Authors:  Sonja Djudjaj; Ina V Martin; Eva M Buhl; Nina J Nothofer; Lin Leng; Marta Piecychna; Jürgen Floege; Jürgen Bernhagen; Richard Bucala; Peter Boor
Journal:  J Am Soc Nephrol       Date:  2017-08-11       Impact factor: 10.121

3.  Suppressor of Cytokine Signaling-1 Peptidomimetic Limits Progression of Diabetic Nephropathy.

Authors:  Carlota Recio; Iolanda Lazaro; Ainhoa Oguiza; Laura Lopez-Sanz; Susana Bernal; Julia Blanco; Jesus Egido; Carmen Gomez-Guerrero
Journal:  J Am Soc Nephrol       Date:  2016-09-08       Impact factor: 10.121

4.  Consistency of Multiple Renal Functional MRI Measurements Over 18 Months.

Authors:  Lu-Ping Li; Jon Thacker; Wei Li; Huan Tan; Chi Wang; Orly Kohn; Stuart Sprague; Pottumarthi Prasad
Journal:  J Magn Reson Imaging       Date:  2018-03-08       Impact factor: 4.813

Review 5.  Fibrosis and progression of autosomal dominant polycystic kidney disease (ADPKD).

Authors:  Jill Norman
Journal:  Biochim Biophys Acta       Date:  2011-07-01

Review 6.  [New approaches in progressive kidney diseases].

Authors:  P Boor
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

7.  Simvastatin ameliorates low-dose streptozotocin-induced type 2 diabetic nephropathy in an experimental rat model.

Authors:  Siwei Zhang; Huali Xu; Xiaofeng Yu; Yuchen Wang; Fanfan Sun; Dayuan Sui
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 8.  MicroRNAs in kidney physiology and disease.

Authors:  Piera Trionfini; Ariela Benigni; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2014-11-11       Impact factor: 28.314

9.  Repeated administration of low-dose cisplatin in mice induces fibrosis.

Authors:  Cierra N Sharp; Mark A Doll; Tess V Dupre; Parag P Shah; Marimuthu Subathra; Deanna Siow; Gavin E Arteel; Judit Megyesi; Levi J Beverly; Leah J Siskind
Journal:  Am J Physiol Renal Physiol       Date:  2016-01-06

Review 10.  Kidney allograft fibrosis: what we learned from latest translational research studies.

Authors:  Simona Granata; Claudia Benedetti; Giovanni Gambaro; Gianluigi Zaza
Journal:  J Nephrol       Date:  2020-03-19       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.